Healthy volunteers test new drug TAK-123 in early safety trial
NCT ID NCT04155567
First seen Nov 20, 2025 · Last updated Jun 10, 2026 · Updated 25 times
Summary
This early-phase study tested the safety and how the body processes TAK-123 in 10 healthy Japanese men aged 20-45. Participants received a single intravenous infusion, and researchers measured drug levels in the blood and monitored for side effects. The study was completed and provides basic safety data, but does not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sekino Clinical Pharmacology Clinic
Toshima-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.